FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2211518972> ?p ?o ?g. }

• W2211518972 endingPage "162" @default.
• W2211518972 startingPage "152" @default.
• W2211518972 abstract "Background The safety and efficacy of front-line nilotinib and dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP) with pre-existing liver and/or renal dysfunction are unknown. Patients and Methods We analyzed the adverse event rates, response rates, and survival rates of 215 patients with CML-CP with or without renal and/or liver dysfunction who had been treated with front-line nilotinib (n = 108) or dasatinib (n = 107). Results The overall median follow-up period was 49 months. At baseline, 6 dasatinib-treated patients (6%) had mild renal dysfunction and 13 (12%) had mild liver dysfunction. Also, 8 nilotinib-treated patients (7%) had mild renal dysfunction, 1 (1%) moderate renal dysfunction, and 9 (8%) mild liver dysfunction. No significant differences were found in the rate of complete cytogenetic response, major molecular response, or molecular response by a 4.5 log reduction on the international scale between the organ function cohorts. Dasatinib- or nilotinib-treated patients with baseline renal dysfunction had a greater incidence of transient reversible acute kidney injury (P = .011 and P < .001), and nilotinib-treated patients with renal dysfunction had a greater incidence of bleeding (P < .001). Conclusion Patients with CML-CP and mild to moderate renal or liver dysfunction can be safely treated with front-line dasatinib or nilotinib and can achieve response rates similar to those of patients with CML-CP without organ dysfunction." @default.
• W2211518972 created "2016-06-24" @default.
• W2211518972 creator A5006104041 @default.
• W2211518972 creator A5015140142 @default.
• W2211518972 creator A5019275087 @default.
• W2211518972 creator A5020340537 @default.
• W2211518972 creator A5028845635 @default.
• W2211518972 creator A5029750735 @default.
• W2211518972 creator A5036349678 @default.
• W2211518972 creator A5049385583 @default.
• W2211518972 creator A5055045706 @default.
• W2211518972 creator A5085419504 @default.
• W2211518972 creator A5088307376 @default.
• W2211518972 creator A5090435894 @default.
• W2211518972 date "2016-03-01" @default.
• W2211518972 modified "2023-10-12" @default.
• W2211518972 title "Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction" @default.
• W2211518972 cites W1455508722 @default.
• W2211518972 cites W1989333836 @default.
• W2211518972 cites W1999958515 @default.
• W2211518972 cites W2009746825 @default.
• W2211518972 cites W2011474502 @default.
• W2211518972 cites W2014839361 @default.
• W2211518972 cites W2052054991 @default.
• W2211518972 cites W2055864845 @default.
• W2211518972 cites W2057206328 @default.
• W2211518972 cites W2061440903 @default.
• W2211518972 cites W2072834954 @default.
• W2211518972 cites W2085342571 @default.
• W2211518972 cites W2091137497 @default.
• W2211518972 cites W2092606584 @default.
• W2211518972 cites W2097799776 @default.
• W2211518972 cites W2106555552 @default.
• W2211518972 cites W2107268345 @default.
• W2211518972 cites W2124196948 @default.
• W2211518972 cites W2143939343 @default.
• W2211518972 cites W2146658081 @default.
• W2211518972 cites W2167325977 @default.
• W2211518972 cites W2168633862 @default.
• W2211518972 cites W2587781815 @default.
• W2211518972 cites W32471882 @default.
• W2211518972 doi "https://doi.org/10.1016/j.clml.2015.12.003" @default.
• W2211518972 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4769134" @default.
• W2211518972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26796981" @default.
• W2211518972 hasPublicationYear "2016" @default.
• W2211518972 type Work @default.
• W2211518972 sameAs 2211518972 @default.
• W2211518972 citedByCount "24" @default.
• W2211518972 countsByYear W22115189722017 @default.
• W2211518972 countsByYear W22115189722019 @default.
• W2211518972 countsByYear W22115189722020 @default.
• W2211518972 countsByYear W22115189722021 @default.
• W2211518972 countsByYear W22115189722022 @default.
• W2211518972 countsByYear W22115189722023 @default.
• W2211518972 crossrefType "journal-article" @default.
• W2211518972 hasAuthorship W2211518972A5006104041 @default.
• W2211518972 hasAuthorship W2211518972A5015140142 @default.
• W2211518972 hasAuthorship W2211518972A5019275087 @default.
• W2211518972 hasAuthorship W2211518972A5020340537 @default.
• W2211518972 hasAuthorship W2211518972A5028845635 @default.
• W2211518972 hasAuthorship W2211518972A5029750735 @default.
• W2211518972 hasAuthorship W2211518972A5036349678 @default.
• W2211518972 hasAuthorship W2211518972A5049385583 @default.
• W2211518972 hasAuthorship W2211518972A5055045706 @default.
• W2211518972 hasAuthorship W2211518972A5085419504 @default.
• W2211518972 hasAuthorship W2211518972A5088307376 @default.
• W2211518972 hasAuthorship W2211518972A5090435894 @default.
• W2211518972 hasBestOaLocation W22115189722 @default.
• W2211518972 hasConcept C126322002 @default.
• W2211518972 hasConcept C126894567 @default.
• W2211518972 hasConcept C197934379 @default.
• W2211518972 hasConcept C2776960273 @default.
• W2211518972 hasConcept C2777413986 @default.
• W2211518972 hasConcept C2777583451 @default.
• W2211518972 hasConcept C2778384902 @default.
• W2211518972 hasConcept C2778426790 @default.
• W2211518972 hasConcept C2778461978 @default.
• W2211518972 hasConcept C2778729363 @default.
• W2211518972 hasConcept C2779536868 @default.
• W2211518972 hasConcept C2991928575 @default.
• W2211518972 hasConcept C71924100 @default.
• W2211518972 hasConcept C90924648 @default.
• W2211518972 hasConceptScore W2211518972C126322002 @default.
• W2211518972 hasConceptScore W2211518972C126894567 @default.
• W2211518972 hasConceptScore W2211518972C197934379 @default.
• W2211518972 hasConceptScore W2211518972C2776960273 @default.
• W2211518972 hasConceptScore W2211518972C2777413986 @default.
• W2211518972 hasConceptScore W2211518972C2777583451 @default.
• W2211518972 hasConceptScore W2211518972C2778384902 @default.
• W2211518972 hasConceptScore W2211518972C2778426790 @default.
• W2211518972 hasConceptScore W2211518972C2778461978 @default.
• W2211518972 hasConceptScore W2211518972C2778729363 @default.
• W2211518972 hasConceptScore W2211518972C2779536868 @default.
• W2211518972 hasConceptScore W2211518972C2991928575 @default.
• W2211518972 hasConceptScore W2211518972C71924100 @default.
• W2211518972 hasConceptScore W2211518972C90924648 @default.
• W2211518972 hasFunder F4320337351 @default.
• W2211518972 hasIssue "3" @default.

• next